Comparison of cetuximab every 2 weeks versus standard once-weekly administration for the first-line treatment of RAS wild-type metastatic colorectal cancer among patients with left- and right-sided primary tumor location

被引：0

作者：

Kasper, S. ^{[1
]}

Cheng, A-L. ^{[2
]}

Rouyer, M. ^{[3
]}

Foch, C. ^{[4
]}

Lamy, F-X. ^{[5
]}

Esser, R. ^{[6
]}

Batech, M. ^{[7
]}

Wong, C. M. J. ^{[8
]}

Zhang, A. ^{[9
]}

Brodowicz, T. ^{[10
]}

Zielinski, C. ^{[11
,12
]}

机构：

[1] Univ Hosp Essen Westdeutsches Tumorzentrum, Med Oncol Dept, Essen, Germany

[2] Natl Taiwan Univ, Canc Ctr, Dept Internal Med & Oncol, Taipei, Taiwan

[3] Univ Bordeaux, Bordeaux PharmacoEpi, Bordeaux, France

[4] Merck KGaA, R&D Global Biostat Epidemiol & Med Writing, Darmstadt, Germany

[5] Merck KGaA, Global Epidemiol Dept, Darmstadt, Germany

[6] Merck KGaA, Global Med Affairs, Darmstadt, Germany

[7] Merck KGaA, Med Oncol, Darmstadt, Germany

[8] Cytel Singapore Pte Ltd, Project Based Serv, Singapore, Singapore

[9] Merck Serono, R&D Global Biostat, Beijing, Peoples R China

[10] Med Univ Vienna, Gen Hosp, Internal Med 1, Dept Med Oncol, Vienna, Austria

[11] Vienna Gen Hosp, Comprehens Canc Ctr, Oncol, Vienna, Austria

[12] Med Univ Vienna, Vienna, Austria

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.936

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

415P

引用

页码：S542 / S543

页数：2

共 50 条

[1] Overall survival with cetuximab every 2 weeks vs standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumor location
Kasper, S.
Cheng, A.
Rouyer, M.
Foch, C.
Lamy, F.
Esser, R.
Batech, M.
Wong, C.
Zhang, A.
Brodowicz, T.
Zielinski, C.
ANNALS OF ONCOLOGY, 2021, 32 : S114 - S114
[2] Overall survival with cetuximab every-2-weeks versus standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumour location
Kasper, Stefan
Foch, Caroline
Esser, Regina
Zhang, Aimar
Cheng, Ann-Lii
Rouyer, Magali
Brodowicz, Thomas
Zielinski, Christoph
EUROPEAN JOURNAL OF CANCER, 2023, 180 : 85 - 88
[3] Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer
Kasper, Stefan
Foch, Caroline
Messinger, Diethelm
Esser, Regina
Lamy, Francois-Xavier
Rothe, Vivien
Chen, Wenfeng
Cheng, Ann-Lii
Rouyer, Magali
Brodowicz, Thomas
Zielinski, Christoph
EUROPEAN JOURNAL OF CANCER, 2021, 144 : 291 - 301
[4] Noninferiority on overall survival of every-2-weeks vs weekly schedule of cetuximab for first-line treatment of RAS wild-type metastatic colorectal cancer
Kasper, S.
Cheng, A-L.
Overkamp, F.
Rouyer, M.
Foch, C.
Lamy, F-X.
Esser, R.
Messinger, D.
Rothe, V.
Chen, W.
Brodowicz, T.
Zielinski, C. C.
ANNALS OF ONCOLOGY, 2019, 30
[5] Noninferiority on Overall Survival of Every-2-Weeks vs Weekly Schedule of Cetuximab for First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer
Kasper-Virchow, Stefan
Cheng, Ann-Lll
Overkamp, Friedrich
Rouyer, Magali
Foch, Caroline
Lamy, Francois-Xavier
Esser, Regina
Messinger, Diethelm
Rothe, Vivien
Chen, Wenfeng
Brodowicz, Thomas
Zielinski, Christoph
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 219 - 220
[6] Association of right-sided colon cancer with poor efficacy of cetuximab in patients with RAS wild-type metastatic colorectal cancer.
Kim, Dalyong
Hong, Yong Sang
Kim, Jeong Eun
Kim, Kyu-Pyo
Lee, Jae-Lyun
Chun, Sung-Min
Kim, Jihun
Jang, Se Jin
Kim, Tae Won
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[7] Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients
Samalin, Emmanuelle
Mazard, Thibault
Assenat, Eric
Rouyer, Magali
de la Fouchardiere, Christelle
Guimbaud, Rosine
Smith, Denis
Portales, Fabienne
Ychou, Marc
Adenis, Antoine
Fiess, Catherine
Lopez-Crapez, Evelyne
Thezenas, Simon
DIGESTIVE AND LIVER DISEASE, 2024, 56 (08) : 1375 - 1381
[8] Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England
Tikhonova, Irina A.
Huxley, Nicola
Snowsill, Tristan
Crathorne, Louise
Varley-Campbell, Jo
Napier, Mark
Hoyle, Martin
PHARMACOECONOMICS, 2018, 36 (07) : 837 - 851
[9] CETUXIMAB IN THE FIRST-LINE TREATMENT OF RAS WILD-TYPE METASTATIC COLORECTAL CANCER WITH LIVER-LIMITED DISEASE
Souza, P., V
Zanini, F. E.
Biglia, L., V
Kim, H. S.
Fahham, L.
VALUE IN HEALTH, 2017, 20 (09) : A875 - A875
[10] Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England
Irina A. Tikhonova
Nicola Huxley
Tristan Snowsill
Louise Crathorne
Jo Varley-Campbell
Mark Napier
Martin Hoyle
PharmacoEconomics, 2018, 36 : 837 - 851

← 1 2 3 4 5 →